<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="159006">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01028846</url>
  </required_header>
  <id_info>
    <org_study_id>2006-414</org_study_id>
    <nct_id>NCT01028846</nct_id>
  </id_info>
  <brief_title>Central Mechanisms That Regulate Glucose Metabolism in Humans</brief_title>
  <official_title>Central Mechanisms That Regulate Glucose Metabolism in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Einstein College of Medicine, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Albert Einstein College of Medicine, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to understand how diazoxide, a medication that has been shown
      to have effects on insulin and other hormone secretion, can regulate the production of sugar
      by the liver.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endogenous Glucose Production</measure>
    <time_frame>4 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose Uptake</measure>
    <time_frame>4 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Diazoxide</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diazoxide</intervention_name>
    <description>4mg-6mg/kg orally once before study</description>
    <arm_group_label>Diazoxide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BP &lt; 130/90 (+-2 meds)

          -  BMI &lt; 35

          -  Normal screening labs (CBC, chemistry, lft's PT/PTT)

          -  No CAD

          -  No first degree relatives with history of CAD or MI (men &lt; 45; women &lt; 55)

          -  Good IV access

          -  Noth other medical problems with exception: HTN (on &lt; or = 2 meds),
             hypercholesterolemia, and stable retinopathy

          -  Non-smoker

          -  Hemoglobin A1C 7.5-11

        Exclusion Criteria:

          -  BP&gt;130/90 (+- medications)

          -  BMI &gt; 35

          -  Abnormal EKG

          -  History of CAD or exertional chest pain

          -  First degree relative with early CAD or MI

          -  Medications for medical or psychiatric conditions including: dofetilide,
             fosphenytoin/phenytoin trichlormethiazide (any thiazide), chlorpromazine and warfarin

          -  &lt; 4 week history of participation in another drug trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Meredith Hawkins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein College of Medicine, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Morgan Drucker, BS</last_name>
    <email>Morgan.drucker@einstein.yu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Albert Einstein College of Medicine of Yeshiva University</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Meredith Hawkins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <lastchanged_date>July 10, 2014</lastchanged_date>
  <firstreceived_date>December 7, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Albert Einstein College of Medicine of Yeshiva University</investigator_affiliation>
    <investigator_full_name>Meredith Hawkins</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Type 2 Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diazoxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
